 GUANGZHOU, China, Aug. 03, 2021 GLOBE NEWSWIRE -- Burning Rock Biotech Limited NASDAQ: BNR, the Company or Burning Rock today announced a global strategic partnership with IMPACT Therapeutics in companion diagnostics CDx development for a pipeline of drugs in the field of synthetic lethality. The two companies will jointly develop CDx for a targeted oncology drug, Senaparib IMP4297, a PARP inhibitor, for the treatment of prostate cancer globally, including CDx submissions to both the U.S. Food and Drug Administration FDA and the National Medical Products Administration of China NMPA. The global program will be supported by Burning Rocks Clinical Laboratory Improvement Amendments CLIA certified and College of American Pathologists CAP accredited labs in Guangzhou, China and California, U.S. Furthermore, the two companies will deepen collaborations in exploring and discovering new biomarkers for a pipeline of targeted drugs. 